These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27827395)

  • 1. Death receptor 5 (DR5) and a 5-gene apoptotic biomarker panel with significant differential diagnostic potential in colorectal cancer.
    Devetzi M; Kosmidou V; Vlassi M; Perysinakis I; Aggeli C; Choreftaki T; Zografos GN; Pintzas A
    Sci Rep; 2016 Nov; 6():36532. PubMed ID: 27827395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noxa upregulation and 5-gene apoptotic biomarker panel in colorectal cancer.
    Kosmidou V; Vlassi M; Anagiotos K; Raftopoulou S; Kalogerakou E; Skarmalioraki S; Aggeli C; Choreftaki T; Zografos G; Pintzas A
    Eur J Clin Invest; 2021 Jan; 51(1):e13353. PubMed ID: 32682341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer.
    Kim SL; Min IS; Park YR; Lee ST; Kim SW
    Int J Oncol; 2018 Dec; 53(6):2789-2799. PubMed ID: 30221676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling.
    Chen X; Kandasamy K; Srivastava RK
    Cancer Res; 2003 Mar; 63(5):1059-66. PubMed ID: 12615723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
    Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
    Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
    Khawaja H; Campbell A; Roberts JZ; Javadi A; O'Reilly P; McArt D; Allen WL; Majkut J; Rehm M; Bardelli A; Di Nicolantonio F; Scott CJ; Kennedy R; Vitale N; Harrison T; Sansom OJ; Longley DB; Evergren E; Van Schaeybroeck S
    Cell Death Dis; 2020 Oct; 11(10):930. PubMed ID: 33122623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells.
    Tang SY; Zhong MZ; Yuan GJ; Hou SP; Yin LL; Jiang H; Yu ZΥ
    Oncol Rep; 2013 Feb; 29(2):474-80. PubMed ID: 23135489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
    Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tetrandrine (TET) Induces Death Receptors Apo Trail R1 (DR4) and Apo Trail R2 (DR5) and Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis.
    Shishodia G; Koul S; Dong Q; Koul HK
    Mol Cancer Ther; 2018 Jun; 17(6):1217-1228. PubMed ID: 29549167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines.
    Laguinge LM; Samara RN; Wang W; El-Deiry WS; Corner G; Augenlicht L; Mishra L; Jessup JM
    Cancer Res; 2008 Feb; 68(3):909-17. PubMed ID: 18245494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAIL.
    Sung B; Ravindran J; Prasad S; Pandey MK; Aggarwal BB
    J Biol Chem; 2010 Nov; 285(46):35418-27. PubMed ID: 20837473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.
    Tse AK; Cao HH; Cheng CY; Kwan HY; Yu H; Fong WF; Yu ZL
    J Invest Dermatol; 2014 May; 134(5):1397-1407. PubMed ID: 24213373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-128 Targets the SIRT1/ROS/DR5 Pathway to Sensitize Colorectal Cancer to TRAIL-Induced Apoptosis.
    Lian B; Yang D; Liu Y; Shi G; Li J; Yan X; Jin K; Liu X; Zhao J; Shang W; Zhang R
    Cell Physiol Biochem; 2018; 49(6):2151-2162. PubMed ID: 30257253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules.
    Taniguchi H; Horinaka M; Yoshida T; Yano K; Goda AE; Yasuda S; Wakada M; Sakai T
    Mol Cancer Ther; 2012 Oct; 11(10):2294-300. PubMed ID: 22784708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
    Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
    Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.